PRE Prenetics Global Limited

bullish track record → $18.33 +0.83 (+4.7%)
Get emailed when PRE changes direction
Mkt Cap $307M 52wk $4.30 - $23.63 Earnings 2026-05-12 53d ago
Factor Model (net -0.1)

Factor Model

net -0.1 1.0 / 10
Est. Revisions
+0.0
Insider Activity
+0.0
Momentum
+0.0
Analyst Rev.
+0.0
Narrative Gap
+0.0

IM8 brand hits $120M ARR in first year

Watch: Watch whether IM8 can sustain ARR growth into Q1 2026 and how management deploys its $171 million cash pile — organic reinvestment or M&A will signal confidence in the model's staying power.

Prenetics Global posted a 480% revenue jump to $92.4 million in 2025, powered by its IM8 brand reaching $120 million in annual recurring revenue within a year of launch. Q4 revenue hit $36.6 million, up 55% from the prior quarter. The company sold its Insighta stake to Tencent for $70 million cash, leaving it with roughly $171 million in liquidity and zero debt.

The IM8 launch has transformed Prenetics from a COVID-testing relic into a recurring-revenue consumer health play with a clean balance sheet. Sequential acceleration in Q4 and strong ARR suggest the brand has real traction, while the Tencent exit gives management dry powder to scale without dilution risk.

Evidence

Fundamentals & Data ▾
Prenetics Global Limited Healthcare · Diagnostics & Research
Mkt Cap
$307M
Beta
0.27
52w Range
$4.30 - $23.63
Short Interest
572,680 3.98%
Days to Cover
2.7 +20%
Technicals downtrend
from 52w Hi
-7.2%
1w return
+2.8%
EPS Estimate
$-0.49 0up / 0dn
Est. Dispersion
0% 1 analysts
Analyst Target
$31 $29 - $36
Options P/C
0.34
Fund Convergence
moderate Renaissance, Citadel
Financials
Revenue
$24M +568% YoY
Gross Margin
60%
Op Margin
-28%
Momentum: accelerating
Top Holders
Renaissance
Citadel
1 signals · latest 55d ago

Get alerted when PRE changes direction

We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.